AZN : Enhertu Approved In U.S. As First HER2 Directed Therapy For HER2 Mutant Metastatic NSCLC
12/8 05:52
(RTTNews) - Daiichi Sankyo and AstraZeneca's (AZN, AZN.L) Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer or NSCLC whose tumors have activating HER2 (ERBB2) muta...